The co-promotion will begin during the first quarter of 2008. Cephalexin, the generic form of Keflex, is said to be the number-one recommended oral antibiotic therapy for uncomplicated skin and skin structure infections.
Philip Pesin, CEO of Auriga, said: “This agreement solidifies Auriga’s commitment to enhance our product portfolio.”